Polycystic ovary syndrome (PCOS);Le syndrome des ovaires polymicrokystiques (SOPMK)

Annales d'Endocrinologie

Volumn 71, Issue 1, 2010, Pages

  Dewailly, D ^a   Hieronimus, S ^b   Mirakian, P ^c   Hugues, J N ^d  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c Clinique de Monplaisir   (France)

^d UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; ESTRADIOL; FOLLITROPIN; GLUCOSE; GONADORELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LUTEINIZING HORMONE; PROGESTERONE; PROLACTIN; THYROTROPIN; TRIACYLGLYCEROL;

ANOVULATION; ARTICLE; DRUG MEGADOSE; ECHOGRAPHY; HUMAN; HYPERANDROGENISM; HYPOGONADOTROPIC HYPOGONADISM; INSULIN RESISTANCE; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PROGESTERONE BLOOD LEVEL; RECOMMENDED DRUG DOSE;

EID: 77249095404     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2009.12.004     Document Type: Article

References (49)

1. Laven J.S., Imani B., and Eijkemans M.J. Fauser BC New approaches to PCOS and other forms of anovulation. Obstet Gynecol Surv 57 (2002) 755-767
2. Norman R.J., Masters L., Milner C.R., Wang J.X., and Davies M.J. Relative risk of conversion from normoglycemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovary syndrome. Hum Reprod 9 (2001) 1995-1998
3. Adams J., Polson D.W., and Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 293 (1986) 355-359
4. Franks S. Polycystic ovary syndrome: a changing perspective (review). Clin Endocrinol 31 (1989) 87-120
5. Carmina E., Koyama T., Chang L., Stanczyk F.Z., and Lobo R.A. Does ethnicity influence the prevalence of adrenal hyperandrogenism in insulin resistance in the polycystic ovary syndrome?. Am J Obstet Gynecol 167 (1992) 1807-1182
6. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab 2006;91:3922-7.
7. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 91 (2006) 781-785
8. Capri workshop ESHRE group. An ovulatory infertility. Hum Reprod 10 (1995) 1549-1553
9. Rowe P.J., Comhaire F.H., and Hargreave T.B. Female partner. WHO manual for the standardized investigation and diagnosis of the infertile couple (2000), Cambridge University Press p 40-67
10. Van Santbrink E.J., Hop W.C., and Fauser B.C. Classification of normogonadotropin infertility: Polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of PCOS. Fertil Steril 67 (1997) 452-458
11. Moller D.E., Cohen O., Yamaguchi Y., Azziz R., Grigorescu F., Eberle A., et al. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes 43 (1994) 247-255
12. Kreisberg R.A. Clinical problem-solving. Half a loaf. N Engl J Med 330 (1994) 1295-1299
13. Waggoner W., Boots L.R., and Azziz R. Total testosterone and DHEAS levels a predictors of androgen-secreting neoplasms: A populational study. Gynecol Endocrinol 13 (1999) 394-400
14. Pache T.D., Hop W.C., Wladimiroff J.W., Schipper J., and Fauser B.C. How to discriminate between normal and polycystic ovaries. Radiol 17 (1992) 589-593
15. Diamanti-Kandarakis E., Koulie C.R., Bergiele A.T., Filandra F.A., Tsianateli T.C., Spina G.G., et al. A survey of the polycystic ovary syndrome in the Greek Island of Lesbos: A hormonal and metabolic profile. J Clin Endocrinol Metab 84 (1999) 4006-4011
16. Wild R.A., Vesely S., Beebe L., Whitsett T., and Owen W. Ferriman Gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 4112-4114
17. Souter I., Sanchez L.A., Perez M., Bartolucci A.A., and Azziz R. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol 191 (2004) 1914-1920
18. Ruutiainen K., Erkkola R., Gronroos M.A., and Irjala K. Influence of body mass index and age on the grade of hair growth in hirsute women of reproductive ages. Fertil Steril 50 (1998) 260-265
19. De Urgarte C.M., Woods K.S., Bartolucci A.A., and Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: Toward a populational definition of hirsutism. J Clin Endocrinol Metab 91 (2006) 1345-1350
20. Slayden S.M., Moran C., Sams Jr. W.M., Boots L.R., and Azziz R. Hyperandrogenemia in patients presenting with acne. Fertil Steril 75 (2001) 889-892
21. Futterweit W., Dunaif A., Yeh C., and Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J M Acad Dermatol 19 (1998) 831-836
22. Jonard S., Robert Y., Cortet C., Decanter C., and Dewailly D. Ultrasound examination of polycystic ovaries: Is it worth counting the follicles?. Hum Reprod 18 (2003) 598-603
23. Balen A.H., Laven J.S., Tan S.L., and Dewailly D. Ultrasound assessment of the polycystic ovary: International consensus definitions. Human Reprod Upd (2003)
24. Bucket W.M., Bouzayen R., Watkin K.L., Tulandi T., and Tan S.L. Ovarian stromal echogenicity in women with normal and polycystic ovaries. Human Reprod 18 (2003) 598-603
25. Dewailly D., Robert Y., Helin I., Ardaens Y., Thomas P., Lemaitre L., et al. Ovarian stromal hypertrophy in hyperandrogenic women. Clin Endocrinol 41 (1994) 557-562
26. Christensen J.T., Boldsoen J., and Westergaard J.G. Ovarian volume in gynecologically healthy women using contraception or using IUD. Acta Obstet Gynecol Scand 76 (1997) 784-789
27. Imani B., Eijkemans M.J., de Jong F.H., Payne N.N., Bouchard P., Giudice L.C., et al. Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 85 (2000) 676-682
28. McDougall M.J., Tan S.L., and Jacobs H.S. IVF and the ovarian hyperstimulation syndrome. Human Reprod 5 (1992) 597-600
29. Swanson M., Sauerbrei E.E., and Cooperberg P.L. Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound 9 (1981) 219-222
30. Fauser B.C., Pache T.D., Lamberts S.W., Hop W.C., de Jong F.H., and Dahl K.D. Serum bioactive and immunoreactive LH and FSH levels in women with cycle abnormalities, with or without PCOD. J Clin Endocrinol Metab 73 (1991) 811-817
31. Taylor A.E., McCourt B., Martin K., Anderson E.J., Adams J., Schoebfeld D., et al. Determinants of abnormal gonadotropin secretion in clinically defined women with PCOS. J Clin Endocrinol Metab 82 (1997) 2248-2256
32. Waldstreicher J., Santoro N.F., Hall H.J.E., Filicori M., and Crowley W.F. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: Indirect evidence of partial gonadotroph desensitization. J Clin Endocrinol Metab 66 (1988) 165-172
33. Srouji S.S., Pagán Y.L., D'Amato F., Dabela A., Jimenez Y., Supko J.G., et al. Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. J Clin Endocrinol Metab 92 (2007) 1347-1352
34. Birken S., McChesney R., Yershova O.O., Gaughan J., Pettersson K., Rechenberg G., et al. Patterns of LHbetacf among women in health and disease. Mol Cell Endocrinol 260-262 (2007) 172-182
35. Ferrannini E., Natali A., Bell P., Cavallo-Perin P., Lalic N., and Mingrone G. Insulin resistance and hypersecretion in obesity. J Clin Invest 30 (1997) 1166-1173
36. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
37. Diamanti-Kandarakis E., Koulie C.R., Alexandraki K., and Spina G.G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 1273-1276
38. Apridonidze T., Essah P., Iurno M., and Nestler J. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1929-1935
39. Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc, 2001;285:2486-2497.
40. Gennarelli G., Holte J., Berglund L., Berne C., Massobrio M., and Lithell H. Prediction models for insulin resistance in the polycystic ovary syndrome. Human Reprod 15 (2000) 2098-2102
41. Legro R.S., Kunselman A.R., Dodson W.C., and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
42. Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K., and Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1999) 141-146
43. Bloomgarden Z.T. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome. Diabetes Care 26 (2003) 1297-1303
44. Bloomgarden Z.T. American association of clinical endocrinologists consensus conference on the insulin resistance syndrome. Diabetes Care 26 (2003) 933-939
45. Legro R.S., Gnatuk C., Kunselman A., and Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 3236-3242
46. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51 (2002) 2796-2803
47. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
48. Anonymous Glucose tolerance and mortality: comparison of WHO and American diabetes association diagnostic criteria. Lancet, 1999, 354: 617-621.
49. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The funagata diabetes study. Diabetes Care 22 (1999) 920-924